

=> b reg;d que sta l5
 FILE 'REGISTRY' ENTERED AT 10:48:48 ON 04 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3
 DICTIONARY FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

L5 STR



VAR G1=1/2/5/6
 VAR G2=C/O/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

=> b hcap;d bib abs hitrn fhitrn l11 tot;d bib abs hitstr l12 tot
 FILE 'HCAPLUS' ENTERED AT 10:50:22 ON 04 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 the American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.





FILE COVERS 1907 - 4 Feb 2008 VOL 148 ISS 6
 FILE LAST UPDATED: 3 Feb 2008 (20080203/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 AN 2005:409232 HCAPLUS
 DN 142:1463739
 TI Preparation of quinazoline analogs as type I receptor tyrosine kinase inhibitors
 IN Wallace, Eli; Topalov, George; Lyssikatos, Joseph; Buckmelter, Alexandre; Zhao, Qian
 PA USA
 SO U.S. Pat. Appl. Publ., 31 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN_CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US20050101616	A1	20050512	2003US-0642440	20030814 <--
AU2004264937	A1	20050224	2004AU-0264937	20040810
CA--2535614	A1	20050224	2004CA-2535614	20040810
US2005043334	A1	20050224	2004US-0914974	20040810
WO2005016346	A1	20050224	2004WO-US26235	20040810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, EE, EG, ES, FI, GB, GD, GE, GH, GR, GU, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, UA, US, VE, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SE, SZ, TG, UG, ZM, ZW, AM, AZ, BY, BG, KE, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
EP----166090	A1	20060531	2004EP-078090	20040810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, HU, IL, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR2004013565	A	20061017	2004BR-0013565	20040810
CN----1852714	A	20061025	2004CN-00026458	20040810
JP20070502295	T	20070208	2006JP-0523384	20040810
IN2006DN00688	A	20070817	2006IN-DN00688	20060210
MX2006PA01767	A	20060512	2006MX-PA01767	20060214
NO2006001171	A	20060410	2006NO-0001171	20060313
PPAI 2003US-0642440	A	20030814		
2004US-5517189	P	20040310		
2004WO-US26235	W	20040810		
GI MAPPAT 142:463739				




AB The title compds. I [A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 substituted by up to three independent R3 groups; X = N, CH, CF, C(CN); R1 = (un)substituted monocyclic or bicyclic aryl or heteroaryl; R2 = H, (un)substituted alkyl; R3 = H, halo, CN, NO2; A = CH2N(R8)C(NR6)NR6R8, Uns; n = 0-1; U = (un)substituted alkyl, alkenyl, alkynyl; Z = II, III; W, V and Y = CR7R8, CR6R9, O, NR6, S, SO, SO2; R6, R8, R9 = H, CF3, alkyl, etc.; with provisos), useful as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer, were prepd. Thus, reacting 4-(3-methyl-4-phenoxyphenylamino)quinazolin-6-carboxaldehyde with hydrazinecarboximidamide in the presence of 1 drop of conc. HCl in MeOH afforded 688 IV. The compds. I have IC50's from less than 1 nM to 50 nM in EGFR/erbB2 assays.
 IT 851545-54-5P 851545-55-6P 851545-56-7P
 851545-57-8P 851545-58-9P 851545-59-0P
 851545-60-3P 851545-61-4P 851545-62-5P
 851545-63-6P 851545-64-7P 851545-65-8P
 851545-66-9P 851545-67-0P 851545-68-1P
 851545-69-2P 851545-70-5P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline analogs as type I receptor tyrosine kinase inhibitors for treating hyperproliferative diseases such as cancer)
 IT 851545-54-5P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline analogs as type I receptor tyrosine kinase inhibitors for treating hyperproliferative diseases such as cancer)
 RN 851545-54-5 HCAPLUS
 CN 4,6-Quinazolinodiamine, N4-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-N6-(3-methyl-2-oxazolidinylidene)- (CA INDEX NAME)




L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2005:160839 HCAPLUS
 DN 142:240462
 TI Preparation of aminoquinazolines as receptor tyrosine kinase inhibitors
 IN Wallace, Eli; Topalov, George; Lyssikatos, Joseph; Buckmelter, Alexandre; Zhao, Qian
 PA USA
 SO U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 642,440.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN_CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US2005043334	A1	20050224	2004US-0914974	20040810
US20050101616	A1	20050512	2003US-0642440	20030814 <--
PRAI 2003US-0642440	A	20030814		
2004US-5517189	P	20040310		
GI MAPPAT 142:240462				




AB Title compds. I [A = O, Z; Q = N-acetamidinoimide; X = N, CH, etc.; Z = dihydroimidazole, etc.; R1 = (hetero)aryl, etc.; R2 = H, alkyl, allyl, etc.; R3 = H, halo, CN, NO2, etc.] are prepared. For instance, (E)-N-[(4-[(3-methyl-4-phenoxyphenyl)amino]quinazolin-6-yl)methyl]amino-2-methoxyacetamide is prepared in two steps from 4-(3-methyl-4-phenoxyphenyl)aminoquinazolin-6-carboxaldehyde, hydrazine and 2-methoxyacetimidic acid Me ester. Compds. of the invention exhibit IC50 values in the range of 1 - 50 nM for ErbB-2 tyrosine kinase. I are useful for the treatment of hyperproliferative diseases such as cancer.
 IT 845271-76-3P, 2-[(4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-6-yl)amino]-3a, 4, 6, 6a-tetrahydrofuro[3,4-d]oxazol-5-carboxylic acid tert-butyl ester 845271-77-4P, 4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]-6-[(4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]oxazol-2-yl)amino]quinazoline 845271-79-6P, 4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]-6-[(3-oxa-1,8-diazaspiro[4.5]dec-1-en-2-yl)amino]quinazoline
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of aminoquinazolines as receptor tyrosine kinase inhibitors)
 IT 845271-69-4P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(4,5-dihydrooxazol-2-yl)amino]quinazoline 845271-72-9P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(3a,4,6,6a-tetrahydrofuro[3,4-d]oxazol-2-yl)amino]quinazoline 845271-74-1P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(1,8-dioxo-1-azaspiro[4.5]dec-1-en-2-yl)amino]quinazoline 845271-75-2P, 6-[(3,8-Dioxo-1-azaspiro[4.5]dec-1-en-2-yl)amino]-4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazoline 845271-78-5P, 1-[2-[(4-[(3-Methyl-4-[(3-methyl-4-[(6-methylpyridin-3-yl)amino]-3a, 4, 6, 6a-tetrahydrofuro[3,4-d]oxazol-5-yl)ethanol 845271-81-0P, 1-[2-[(4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-6-yl)amino]-3-oxa-1,8-diazaspiro[4.5]dec-1-en-2-yl)ethanol 845271-82-1P, 6-[(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]-4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazoline 845271-85-4P, 4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(1-oxa-3,8-diazaspiro[4.5]dec-2-en-2-yl)amino]quinazoline 845271-85-4P, 1-[2-[(4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-6-yl)amino]-3-oxa-1,8-diazaspiro[4.5]dec-2-en-2-yl)ethanol 845271-87-6P, 4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-6-yl)amino]-4,5-dihydrooxazol-4-yl)methanol 845271-88-7P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(4,5-dihydrooxazol-2-yl)amino]quinazoline 845271-89-8P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(4,5-dihydrooxazol-2-yl)amino]quinazoline 845271-90-9P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(4,5-dihydrooxazol-2-yl)amino]quinazoline 845271-91-2P, 4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(4,5-dihydrooxazol-2-yl)amino]quinazoline 845271-92-3P, 6-[(5,5-Dimethyl-4,5-dihydrooxazol-2-yl)amino]-4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazoline 845271-93-4P, 4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(4,5-dihydrooxazol-2-yl)amino]quinazoline 845271-94-5P, 4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(4-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845271-95-6P, 4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(1,8-dioxo-3-azaspiro[4.5]dec-2-en-2-yl)amino]quinazoline 845271-96-7P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(5-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845271-97-8P, 4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]-6-[(3a,4,6,6a-tetrahydrofuro[3,4-d]oxazol-2-yl)amino]quinazoline 845271-98-9P, rel-(1R)-1-[(5S)-5-Methyl-2-[(4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-6-yl)amino]-4,5-dihydrooxazol-5-yl)ethanol 845271-99-0P, 6-[(4,5-Dihydrooxazol-2-yl)amino]-4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazoline 845272-00-6P, [2-[(4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-6-yl)amino]-4-methyl-4,5-dihydrooxazol-4-yl)methanol 845272-01-7P, rel-(1R)-1-[(5S)-2-[(4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-6-yl)amino]-5-methyl-4,5-dihydrooxazol-5-yl)ethanol 845272-02-8P, 4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(4,4-dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-03-9P, rel-(1R)-1-[(5S)-2-[(4-[(3-Fluorobenzyl)oxy]-3-chlorophenyl)amino]quinazolin-6-yl)amino]-5-methyl-4,5-dihydrooxazol-5-yl)ethanol 845272-04-0P, 6-[(5-Methyl-4,5-dihydrooxazol-2-yl)amino]-4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazoline 845272-05-1P, 4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(4-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-06-2P, 4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(1,8-dioxo-3-azaspiro[4.5]dec-2-en-2-yl)amino]quinazoline 845272-07-3P, 6-[(4-Methyl-4,5-dihydrooxazol-2-yl)amino]-4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazoline 845272-08-4P, 4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(3a,4,6,6a-tetrahydrofuro[3,4-d]oxazol-2-yl)amino]quinazoline 845272-09-5P, 4-[(3-Methyl-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(3a,4,6,6a-tetrahydrofuro[3,4-d]oxazol-2-yl)amino]quinazoline 845272-10-6P, 4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(5-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-11-9P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(4-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-12-0P, 4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]oxazol-2-yl)amino]quinazoline 845272-13-1P, 4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]oxazol-2-yl)amino]quinazoline 845272-14-2P, 4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]oxazol-2-yl)amino]quinazoline 845272-15-3P, 4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-[(1,8-dioxo-3-azaspiro[4.5]dec-2-en-2-yl)amino]quinazoline 845272-16-4P, 1-[2-[(4-[(3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl)amino]-6-yl)amino]-3-oxa-1,8-diazaspiro[4.5]dec-2-en-2-yl)ethanol 845272-17-5P, 4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(6-oxa-4-azaspiro[2.4]hept-4-en-5-yl)amino]quinazoline 845272-18-6P, 1-[2-[(4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-6-yl)amino]-4-hydroxymethyl-4,5-dihydrooxazol-4-yl)methanol 845272-19-7P, (1R)-1-[(4S)-2-[(4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]quinazolin-6-yl)amino]-4,5-dihydrooxazol-4-yl)ethanol 845272-20-8P, (R)-4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(4-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-21-9P, (S)-4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(4-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-22-2P, (S)-4-[(3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl)amino]-6-[(4-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-23-3P, (S)-4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(5-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-24-4P, (R)-4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-[(5-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-25-5P, 4-[(4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]-6-yl)amino]-3-methyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-26-6P, 4-[(3-Methyl-4-[(pyridin-3-yl)oxy]phenyl)amino]-6-[(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-27-7P, 4-[(4-[(3-Fluorobenzyl)oxy]-3-yl)oxy]-3-methylphenylamino]-6-[(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-28-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-29-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-30-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-31-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-32-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-33-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-34-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-35-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-36-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-37-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-38-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-39-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-40-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-41-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-42-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-43-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-44-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-45-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-46-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-47-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-48-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-49-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-50-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-51-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-52-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-53-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-54-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-55-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-56-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-57-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-58-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-59-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-60-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-61-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-62-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-63-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-64-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-65-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-66-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-67-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-68-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-69-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-70-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-71-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-72-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-73-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-74-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-75-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-76-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-77-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-78-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-79-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-80-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-81-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-82-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-83-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-84-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-85-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-86-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-87-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-88-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-89-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-90-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-91-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-92-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-93-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-94-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-95-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-96-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-97-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-98-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845272-99-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-00-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-01-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-02-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-03-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-04-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-05-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-06-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-07-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-08-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-09-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-10-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-11-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-12-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-13-3P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-14-4P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-15-5P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-16-6P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-17-7P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-18-8P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-19-9P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-20-0P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-21-1P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-22-2P, 4-[(4-Dimethyl-4,5-dihydrooxazol-2-yl)amino]quinazoline 845273-23-3


L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 yl amino]quinazoline 845272-30-2P, 4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]-6-[[4,5-dihydrooxazol-2-yl(methyl)amino]quinazolin-6-yl]amino]-3-oxa-1,8-diazaspiro[4.5]dec-1-ene-8-carboxylic acid tert-butyl ester 845271-84-3, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-6-yl]amino]-1-oxa-3,8-diazaspiro[4.5]dec-2-ene-8-carboxylic acid tert-butyl ester 845271-86-5, 2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-6-yl]amino]-1-oxa-3,8-diazaspiro[4.5]dec-2-ene-8-carboxylic acid tert-butyl ester 845272-13-1, 2-[[4-[[3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl]amino]quinazolin-6-yl]amino]-3a,4,6,6a-tetrahydropyrrolo[3,4-d]oxazole-5-carboxylic acid tert-butyl ester 845272-15-3, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-6-yl]amino]-3a,4,6,6a-tetrahydropyrrolo[3,4-d]oxazole-5-carboxylic acid tert-butyl ester 845272-20-0, 6-[[4(5)-4-((1R)-1-(tert-Butoxy)ethyl)-4,5-dihydrooxazol-2-yl]amino]-4-[[3-chloro-4-[(thiazol-2-yl)methoxy]phenyl]amino]quinazoline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aminoquinazolines as receptor tyrosine kinase inhibitors)
 IT 845271-80-9, 2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-6-yl]amino]-3-oxa-1,8-diazaspiro[4.5]dec-1-ene-8-carboxylic acid tert-butyl ester 845271-84-3, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-6-yl]amino]-1-oxa-3,8-diazaspiro[4.5]dec-2-ene-8-carboxylic acid tert-butyl ester 845271-86-5, 2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-6-yl]amino]-1-oxa-3,8-diazaspiro[4.5]dec-2-ene-8-carboxylic acid tert-butyl ester 845272-13-1, 2-[[4-[[3-Chloro-4-[(thiazol-2-yl)methoxy]phenyl]amino]quinazolin-6-yl]amino]-3a,4,6,6a-tetrahydropyrrolo[3,4-d]oxazole-5-carboxylic acid tert-butyl ester 845272-15-3, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-6-yl]amino]-3a,4,6,6a-tetrahydropyrrolo[3,4-d]oxazole-5-carboxylic acid tert-butyl ester 845272-20-0, 6-[[4(5)-4-((1R)-1-(tert-Butoxy)ethyl)-4,5-dihydrooxazol-2-yl]amino]-4-[[3-chloro-4-[(thiazol-2-yl)methoxy]phenyl]amino]quinazoline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aminoquinazolines as receptor tyrosine kinase inhibitors)
 IT 845271-76-3P, 2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-6-yl]amino]-3a,4,6,6a-tetrahydropyrrolo[3,4-d]oxazole-5-carboxylic acid tert-butyl ester
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminoquinazolines as receptor tyrosine kinase inhibitors)
 CN 845271-76-3 HCAPLUS
 RN 5H-Pyrrolo[3,4-d]oxazole-5-carboxylic acid, 3a,4,6,6a-tetrahydro-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 937264-92-1P 937265-13-9P 937266-01-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of diarylamines as ErbB inhibitors)
 RN 937263-22-4 HCAPLUS
 CN 4,6-Quinazolidinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-[(2-methyl-5-benzoxazolyl)oxy]phenyl]- (CA INDEX NAME)



RN 937263-27-9 HCAPLUS
 CN 4,6-Quinazolidinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-[(2-methyl-6-benzoxazolyl)oxy]phenyl]- (CA INDEX NAME)



RN 937263-28-0 HCAPLUS
 CN 4,6-Quinazolidinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-[(2-methyl-5-benzothiazolyl)oxy]phenyl]- (CA INDEX NAME)



RN 937263-29-1 HCAPLUS
 CN 4,6-Quinazolidinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-[(2-methyl-6-benzothiazolyl)oxy]phenyl]- (CA INDEX NAME)



L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 AN 2007365407 HCAPLUS
 DN 147:9943
 TI Diarylamines as ErbB inhibitors, their preparation, pharmaceutical compositions, and use in therapy
 IN Lyssikatos, Joseph P.; Marnett, Fredrik P.; Zhao, Qian; Greschuk, Julie Marie
 PA Array Biopharma, Inc., USA
 SO PCT Int. Appl., 17pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2007059257	A2	20070524	2006WO-US44431	20061115
WO2007059257	A3	20070823		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DS, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KS, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, ME, NA, NG, NI, NO, NE, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 PRAI 2005US-736288P P 20051115
 2006US-817019P P 20060628
 OS MARPAT 147:9943
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to diarylamine compds. of formula I, which are inhibitors of epidermal growth factor receptor (ErbB). In compds. I, Y is N or C-CN; A is O, C(O), S, SO, or SO₂; E is unsubstituted bicyclic nitrogen-containing heteroaryl; R₁ is H or alkyl; n is 0-4; each R₂ is independently selected from halo, cyano, nitro, alkyl, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, arido, alkylthio, alkoxy, acyl, alkoxyacarbonyl, etc.; and R₃ and R₄, together with the carbon atoms to which they are attached, form a substituted fused Ph ring or a substituted fused 5- or 6-membered heteroaryl ring; including pharmaceutically acceptable salts thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable diluent or carrier, as well as to the use of the compns. for the treatment of hyperproliferative diseases, such as cancer and inflammation. Substitution of 2-chloro-4-nitropyridine with benzyl alc. followed by substitution with hydrazine, heterocyclization with tri-Me orthoformate, and hydrogenation gave triazolopyridinol II, which underwent substitution of 1-fluoro-2-methyl-4-nitrobenzene and hydrogenation to form aniline III. Condensation of 2-amino-5-nitrobenzonitrile with DMF di-Me acetal followed by hydrogenation, addition to thiocarbonyldiimidazole, and substitution with 2-amino-2-methylpropan-1-ol resulted in the formation of thiourea IV, which was cyclized with aniline III and cyclized to the oxazoline with tosyl chloride to give diarylamine V. The compds. of the invention, e.g., V, are inhibitors of ErbB (no data).

IT 937263-22-4P 937263-27-9P 937263-28-0P
 937263-29-1P 937263-30-4P 937263-31-5P
 937263-32-6P 937263-33-7P 937263-34-8P
 937263-37-1P 937263-43-9P 937263-45-1P
 937263-49-5P 937263-50-8P 937263-61-1P
 937263-62-2P 937263-77-9P 937263-78-0P
 937263-79-1P 937263-81-5P 937263-93-9P
 937264-33-0P 937264-55-6P 937264-82-9P


L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 937263-30-4 HCAPLUS
 CN 4,6-Quinazolidinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-[(6-quinolinyl)oxy]phenyl]- (CA INDEX NAME)



RN 937263-31-5 HCAPLUS
 CN 4,6-Quinazolidinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-[(7-isoquinolinyl)oxy]phenyl]- (CA INDEX NAME)




RN 937263-32-6 HCAPLUS
 CN 4,6-Quinazolidinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-[(7-quinolinyl)oxy]phenyl]- (CA INDEX NAME)




RN 937263-33-7 HCAPLUS
 CN 4,6-Quinazolidinediamine, N4-[4-(6-benzothiazolyl)oxy]-3-methylphenyl]-N6-


L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(4,5-dihydro-4,4-dimethyl-2-oxazolyl)- (CA INDEX NAME)



RN 937263-34-8 HCAPLUS
CN 4,6-Quinazolinodiamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4-triazolo[4,3-a]pyridin-7-yloxy)phenyl)- (CA INDEX NAME)




RN 937263-37-1 HCAPLUS
CN 4,6-Quinazolinodiamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(4-(imidazo[1,2-a]pyridin-7-yloxy)-3-methylphenyl)- (CA INDEX NAME)




RN 937263-43-9 HCAPLUS
CN 4,6-Quinazolinodiamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4-triazolo[1,5-a]pyridin-7-yloxy)phenyl)- (CA INDEX NAME)

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 937263-61-1 HCAPLUS
CN 4,6-Quinazolinodiamine, N4-[4-(imidazo[1,2-a]pyridin-7-yloxy)-3-methylphenyl]-N6-(3-methyl-2-thiazolidinylidene)-, [N6(S)]- (CA INDEX NAME)

Double bond geometry as shown.




RN 937263-62-2 HCAPLUS
CN 4,6-Quinazolinodiamine, N4-[4-(imidazo[1,2-a]pyridin-7-yloxy)-3-methylphenyl]-N6-(4-methyl-2-thiazolyl)- (CA INDEX NAME)




RN 937263-77-9 HCAPLUS
CN 4,6-Quinazolinodiamine, N4-[3-chloro-2-fluoro-4-((1,2,4-triazolo[1,5-a]pyridin-7-yloxy)phenyl)-N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)- (CA INDEX NAME)


L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 937263-45-1 HCAPLUS
CN 4,6-Quinazolinodiamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1-methyl-1H-benzimidazol-5-yl)oxy)phenyl)- (CA INDEX NAME)




RN 937263-49-5 HCAPLUS
CN 4,6-Quinazolinodiamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((2-methylimidazo[1,2-a]pyridin-7-yl)oxy)phenyl)- (CA INDEX NAME)




RN 937263-50-8 HCAPLUS
CN 4,6-Quinazolinodiamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(4-(imidazo[1,2-a]pyridin-6-yloxy)-3-methylphenyl)- (CA INDEX NAME)

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 937263-78-0 HCAPLUS
CN 4,6-Quinazolinodiamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(2-fluoro-3-methyl-4-((1,2,4-triazolo[1,5-a]pyridin-7-yloxy)phenyl)- (CA INDEX NAME)




RN 937263-79-1 HCAPLUS
CN 4,6-Quinazolinodiamine, N6-[(4R)-4,5-dihydro-4-methyl-2-oxazolyl]-N4-(3-methyl-4-((1,2,4-triazolo[1,5-a]pyridin-7-yloxy)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 937263-81-5 HCAPLUS
CN 4-Oxazolemethanol, 4,5-dihydro-4-methyl-2-[[4-[[3-methyl-4-((1,2,4-triazolo[1,5-a]pyridin-7-yloxy)phenyl]amino)-6-quinazolinyl]amino]- (CA INDEX NAME)


L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 937263-93-9 HCAPLUS
 CN 4,6-Quinazolinodiamine, N4-[4-(5-benzothiazolyloxy)-3-methylphenyl]-N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)- (CA INDEX NAME)




RN 937264-33-0 HCAPLUS
 CN 4,6-Quinazolinodiamine, N4-[3-chloro-4-((1,2,4)triazolo[1,5-a]pyridin-7-yloxy)phenyl]-N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)- (CA INDEX NAME)



RN 937264-55-6 HCAPLUS
 CN 4,6-Quinazolinodiamine, N4-[4-(imidazo[1,2-a]pyridin-7-yloxy)-3-methylphenyl]-N6-2-thiazolyl- (CA INDEX NAME)




L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)


RN 937264-82-9 HCAPLUS
 CN 4,6-Quinazolinodiamine, N4-[3-methyl-4-((1,2,4)triazolo[1,5-a]pyridin-7-yloxy)phenyl]-N6-2-thiazolyl- (CA INDEX NAME)



RN 937264-92-1 HCAPLUS
 CN 4,6-Quinazolinodiamine, N4-[3-methyl-4-((1,2,4)triazolo[1,5-a]pyridin-7-yloxy)phenyl]-N6-4-oxa-4-azaspiro[2.4]hept-4-en-5-yl- (CA INDEX NAME)



RN 937265-13-9 HCAPLUS
 CN 4,6-Quinazolinodiamine, N4-[3-methyl-4-((1-methyl-1H-benzimidazol-5-yl)oxy)phenyl]-N6-2-thiazolyl- (CA INDEX NAME)



RN 937266-01-8 HCAPLUS
 CN 4,6-Quinazolinodiamine, N6-(4,5-dihydro-4,4-dimethyl-2-thiazolyl)-N4-[3-methyl-4-((1,2,4)triazolo[1,5-a]pyridin-7-yloxy)phenyl]- (CA INDEX NAME)

=> => d his

FILE 'HCAPLUS' ENTERED AT 10:25:39 ON 04 FEB 2008
L1 2 US20050101616/PN

FILE 'REGISTRY' ENTERED AT 10:26:02 ON 04 FEB 2008

FILE 'HCAPLUS' ENTERED AT 10:26:02 ON 04 FEB 2008
L2 TRA L1 1- RN : 171 TERMS

FILE 'REGISTRY' ENTERED AT 10:26:02 ON 04 FEB 2008

L3 171 SEA L2
L4 124 L3 AND NCNC3-C6/ES
L5 STR
L6 4 L5
L7 102 L5 FULL
SAV TEM L7 J440C1R/A
L8 75 L7 AND L4
L9 27 L7 NOT L8

FILE 'HCAPLUS' ENTERED AT 10:32:26 ON 04 FEB 2008

L10 2 L8
L11 2 L10 AND L1
L12 1 L9

FILE 'HCAOLD' ENTERED AT 10:50:35 ON 04 FEB 2008

L13 0 L8
L14 0 L9

=>